NextRNA Therapeutics
PrivateLast Round
Series A
Mar 1, 2022
Total Funding Raised
$56.1M
Company Overview
NextRNA Therapeutics is a biotechnology company that developed small molecule therapeutics targeting dysregulated long non-coding RNAs (lncRNAs) to treat diseases in oncology and neuroscience.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NextRNA Therapeutics Comparables
Compare NextRNA Therapeutics with similar companies based on industry and business-model similarity.
NextRNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 1, 2022 | ||||
| Seed | Mar 1, 2022 |
Key People
Founding team and executive leadership
NextRNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | Seed, Series A |
| Circle Squared Alternative Investments | Series A |
| Evans Capital | Seed, Series A |
| Rivas Capital | Seed, Series A |
| Willett Advisors | Seed, Series A |
| Cobro Ventures | Seed, Series A |
| LightChain Capital | Seed, Series A |
NextRNA Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about NextRNA Therapeutics's valuation, stock price, and market status.